112 Genfome-wide shRNA Screening Defines the SUMO-activating Enzyme (SAE1/2) as a Novel Therapeutic Target for Tumors Driven by c-Myc Oncogenesis

Sumoylation is the Posttranslational modification gaining most of the research interest recently. Sumoylation is involved in various crucial functions of the cell such as regulation of cell cycle, DNA damage repair, apoptosis etc. Oncology is advancing in radiotherapy, targeted chemotherapy, various forms of immunotherapy and targeted gene therapy. Researches are being conducted to prove its connotation with a variety of cancers and inhibitors are being developed to obstruct the fatal effect caused by misbalance of the SUMO-catalytic cycle. It has been shown that upregulation of certain enzymes of Sumoylation correlates with cancer incidence in most of the cases. But, in some cases down-regulation also associates with cancer invasion such as under-expression of UBC9 in initial stage breast cancer. This can aid in future study, treatment and diagnosis of a variety of cancers including breast cancer, prostate cancer, lung adenocarcinoma, melanoma, multiple myeloma etc. Various mechanistic assays are being developed and used to identify potential inhibitors against the dysregulated proteins of Sumoylation. This review summarizes the normal roles of the enzymes involved in the SUMO catalytic cycle, their misbalanced regulation leading to tumorigenesis and nearly all the potent inhibitors identified till now.

show abstract

Sumoylation as an Emerging Target in Therapeutics against Cancer

Liu

Wang

Jiang

et al. 2020

CPD

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

112 Genfome-wide shRNA Screening Defines the SUMO-activating Enzyme (SAE1/2) as a Novel Therapeutic Target for Tumors Driven by c-Myc Oncogenesis

Cited by 1 publication

References 0 publications

Sumoylation as an Emerging Target in Therapeutics against Cancer

Sumoylation as an Emerging Target in Therapeutics against Cancer

Contact Info

Product

Resources

About